NRSN Profile
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology firm based in Herzliya, Israel, is dedicated to the discovery and development of innovative treatments for neurodegenerative diseases. Established in 2017, the company specializes in advancing therapies aimed at addressing the complex challenges associated with debilitating neurological conditions. NeuroSense Therapeutics focuses on identifying novel solutions to improve the quality of life for patients suffering from severe and progressive disorders.
The company's lead therapeutic candidate is PrimeC, an extended-release oral formulation that combines ciprofloxacin and celecoxib in a fixed dose. This investigational drug is being developed for the treatment of amyotrophic lateral sclerosis (ALS), a severe neurodegenerative condition characterized by the progressive degeneration of motor neurons. PrimeC is designed to target multiple pathways involved in ALS, potentially offering a new approach to managing this debilitating disease.
In addition to PrimeC, NeuroSense Therapeutics has a robust preclinical pipeline focused on other neurodegenerative disorders. StabiliC is being developed as a treatment for Parkinson’s disease, aiming to address the motor and non-motor symptoms associated with this chronic condition. Similarly, CogniC is under investigation for Alzheimer’s disease, targeting cognitive decline and aiming to modify disease progression. These projects reflect the company's commitment to tackling a broad spectrum of neurodegenerative diseases with innovative and effective therapies.
NeuroSense Therapeutics is actively advancing its research and development efforts to bring these promising treatments to clinical use. By leveraging a deep understanding of neurodegenerative diseases and pursuing cutting-edge research, the company strives to make significant contributions to the field of neurology. Its focus on developing novel therapies underscores its dedication to addressing unmet medical needs and improving outcomes for patients affected by severe neurological conditions.
|
